Research progress of immune factors associated with patients discontinuing of tyrosine kinase inhibitor for chronic myeloid leukemia

Abstract

Tyrosine kinase inhibitor (TKI) therapy has significant improved the survival and prognosis of patients with chronic myeloid leukemia(CML). Long-term therapy of TKI drugs not only has produced a heavy financial burden of patients, but also results in chronic adverse effects. At present, the treatment-free remission (TFR) has been gradually regarded as the new treatment target for patients with CML.The key to recurrence of CML patients who discontinued of TKI is dependent whether the immune system maintains a sustained TFR. In this paper, immune factors associated with discontinuation of TKI for patients with CML, such as natural killer (NK) cells, killer-cell immunoglobulin-like receptor (KIR), proteinase-1 specific cytotoxic T lymphocyte (PR1-CTL), myeloid derived suppressor cells (MDSC), regulatory T cells (Treg), CD86+ plasmacytoid dendritic cells(pDC), L-selectin(CD62L) and soluble CD62L(sCD62L) were reviewed. Key words: Leukemia, myelogenous, chronic, BCR-ABL positive; Tyrosine kinase inhibitor; Drug resistence, neoplasm; Treatment-free remission; Immunity cellular; Discontinuation